Company / Interest Expense
Actinium Pharmaceuticals, Inc. Interest Expense History
FY2011-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$1.1M
FY2023
5-year range
$178.0K / $1.1M
FY2019-FY2023
Trend
+472.1%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Interest Expense changed +472% YoY in FY2023, a notable deviation from the 3-year average annual change of +227%.
Based on SEC 10-K filings.
$1M in FY2023.
Increased from $178,000 to $1M over the past 2 years.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Actinium Pharmaceuticals, Inc.'s interest expense has grown for 3 consecutive years.
- In FY2023, interest expense increased 472.1% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $1.1M | +472.1% |
| FY2022 | $190.0K | +6.7% |
| FY2021 | $178.0K | +201.7% |
| FY2011 | -$175.1K | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026